Ladiratuzumab vedotin is a Monoclonal Antibody Conjugated owned by Seagen, and is involved in 4 clinical trials, which are ongoing.
Ladiratuzumab vedotin (SGN-LIV1A) is an antibody-drug conjugate that targets LIV-1 (a zinc transporter), which is expressed in most subtypes of metastatic breast cancer. Zinc is essential for normal cell growth and is tightly controlled in cells by two families of zinc transporters. The aberrant expression of zinc transporters from the LIV-1 family of ZIP (Zrt/Irt-like protein) transporters is implicated in breast cancer. Upon internalization by LIV-1-positive tumor cells, anti-LIV-1 antibody-drug conjugate SGN-LIV1A undergoes enzymatic cleavage to release MMAE into the cytosol. MMAE binds to and inhibits tubulin polymerization, which may result in G2/M phase cell cycle arrest and apoptosis in LIV-1-expressing tumor cells.
The revenue for Ladiratuzumab vedotin is expected to reach a total of $356m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Ladiratuzumab vedotin NPV Report.
Ladiratuzumab vedotin Overview
Ladiratuzumab vedotin (SGN-LIV1A) is under development for the treatment of HR positive metastatic breast cancer, HER2 positive and negative metastatic breast cancer, LIV-1-positive metastatic triple negative breast cancer, small-cell lung cancer, squamous non-small cell lung cancer, non-squamous non-small cell lung cancer, head and neck cancer squamous cell carcinoma, esophageal squamous cell carcinoma gastric cancer, adenocarcinoma of the gastroesophageal junction, metastatic castration-resistant prostate cancer and malignant melanoma. It is administered through the intravenous route. The drug candidate is an antibody-drug conjugate which is comprised of an anti-LIV-1 monoclonal antibody linked to a synthetic cell-killing agent called monomethyl auristatin E (MMAE). The drug candidate is developed based on antibody-drug conjugate (ADC) technology. It was also under development for the treatment of cervical cancer.
Merck & Co Overview
Merck & Co (Merck) is a biopharmaceutical company focused on the discovery, development, manufacturing and marketing of prescription medicines, biologic therapies, vaccines and animal health products. It offers prescription products for therapy areas related to cardiovascular, cancer, immune disorders, infectious, respiratory and women’s diseases, and diabetes. The company provides animal health products such as vaccines, poultry products, livestock products and aquaculture products. Merck sells medicines to drug wholesalers, retailers, hospitals, government agencies and managed health care providers; and animal health products to veterinarians, distributors and animal producers. The company and its subsidiaries operate in the Americas, Europe, the Middle East, Africa, Asia Pacific, and Latin America. Merck is known as MSD outside the US and Canada and is headquartered in Kenilworth, New Jersey, the US.
The company reported revenues of (US Dollars) US$48,704 million for the fiscal year ended December 2021 (FY2021), an increase of 17.3% over FY2020. In FY2021, the company’s operating margin was 25.7%, compared to an operating margin of 12% in FY2020. In FY2021, the company recorded a net margin of 26.8%, compared to a net margin of 17% in FY2020. The company reported revenues of US$14,959 million for the third quarter ended September 2022, an increase of 2.5% over the previous quarter.
Quick View – Ladiratuzumab vedotin
|Highest Development Stage|